ACAD Relative Valuation - ACADIA Pharmaceuticals Inc - Alpha Spread

ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

Watchlist Manager
ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Watchlist
Price: 16.42 USD 0.55% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
ACADIA Pharmaceuticals Inc?
Write Note

Relative Value

The Relative Value of one ACAD stock under the Base Case scenario is 25.34 USD. Compared to the current market price of 16.42 USD, ACADIA Pharmaceuticals Inc is Undervalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACAD Relative Value
Base Case
25.34 USD
Undervaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
70
Median 3Y
5.9
Median 5Y
7.2
Industry
7.7
Forward
2.8
vs History
3
vs Industry
Median 3Y
-17.2
Median 5Y
-23
Industry
23.9
Forward
30.8
vs History
12
vs Industry
4
Median 3Y
-22.7
Median 5Y
-29.3
Industry
22.2
vs History
7
vs Industry
4
Median 3Y
-24.7
Median 5Y
-29.1
Industry
24
vs History
92
vs Industry
14
Median 3Y
6.5
Median 5Y
8.5
Industry
2.5
vs History
95
vs Industry
63
Median 3Y
5.1
Median 5Y
6.4
Industry
7.4
Forward
2.3
vs History
95
vs Industry
63
Median 3Y
5.2
Median 5Y
6.6
Industry
8.5
vs History
7
vs Industry
0
Median 3Y
-12
Median 5Y
-19.2
Industry
5.1
Forward
24.7
vs History
3
vs Industry
Median 3Y
-14.3
Median 5Y
-19.5
Industry
4.7
Forward
25.2
vs History
12
vs Industry
4
Median 3Y
-19
Median 5Y
-25.8
Industry
6.6
vs History
7
vs Industry
4
Median 3Y
-20.7
Median 5Y
-25.7
Industry
4.7
vs History
95
vs Industry
27
Median 3Y
13.7
Median 5Y
16.8
Industry
4.7

Multiples Across Competitors

ACAD Competitors Multiples
ACADIA Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
2.7B USD 3.1 89.2 64.9 97.5
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
127.8B USD 9.5 29.6 25.9 28.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.3B USD 11.9 -251.7 26.8 28.1
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 27.9
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
US
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Average P/E: 62.8
89.2
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.6
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -251.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A

See Also

Discover More
Back to Top